Results for:

Long COVID

< Back to all posts

Does Paxlovid reduce the risk of long COVID?

Infectious Diseases Long COVID Treatments

Unfortunately, data is mixed on the usefulness of Paxlovid for the prevention of long COVID. We need more data, including clinical trials that are carefully designed, to evaluate whether or not there is a benefit. Long COVID, also known as post-acute sequelae of COVID-19, refers to lingering symptoms that emerge in some individuals following a SARS-CoV-2 infection. Read more…

Live Q&A on Long COVID

Long COVID

Join Those Nerdy Girls Live to learn about long COVID (PASC) with immunologist Dr. Liz Marnik. Friday, March 15 at 4 pm EDT/1 pm PDT Hosted by: – Liz Marnik, PhD: Assistant Professor & Science Communicator (@sciencewhizliz) – Chana Davis, PhD: TNG Contributing Writer & Founder of Fueled by Science

What does a deep dive into the immune system of people with long COVID reveal?

Long COVID

New study alert! A recent study available as a preprint found multiple biologic similarities in people experiencing long COVID. This early research informs future studies on the diagnosis of long COVID using self-reported symptoms and laboratory data as well as potential target mechanisms for the treatment of this debilitating condition. The underlying cause of long Read more…

Why do long COVID estimates seem to vary so much from study to study?

Data and Metrics Data Literacy Long COVID

A: Different case definitions, study participants, data collection methods, and study timing across studies. TL:DR: Current estimates of the proportion of COVID-19 cases that develop long COVID range from 3-20% and have been as high as 50%! Considering how studies differ can help us understand why estimates vary so much across studies. Things to keep Read more…